Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy

Thumbnail Image
Download
Name

Wagner-2016-Dose-Dependent Regulation of Alter.pdf

Size

3.23 MB

Format

Adobe PDF

Checksum (MD5)

010158c21bad500fa85046c214dc90f1

Author(s)
Wagner, Stacey D.
•
Struck, Adam J.
•
Gupta, Riti
•
Farnsworth, Dylan R.
•
Mahady, Amy E.
•
Eichinger, Katy
•
Thornton, Charles A.
•
Berglund, J. Andrew
•
Wang, Eric T
Date Issued
September 2016
Journal
PLOS Genetics
Publisher
Public Library of Science
Citation
Wagner, Stacey D. et al. “Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy.” Ed. Gregory A. Cox. PLOS Genetics 12.9 (2016): e1006316.
Version
Final published version
Abstract
Alternative splicing is a regulated process that results in expression of specific mRNA and protein isoforms. Alternative splicing factors determine the relative abundance of each isoform. Here we focus on MBNL1, a splicing factor misregulated in the disease myotonic dystrophy. By altering the concentration of MBNL1 in cells across a broad dynamic range, we show that different splicing events require different amounts of MBNL1 for half-maximal response, and respond more or less steeply to MBNL1. Motifs around MBNL1 exon 5 were studied to assess how cis-elements mediate the MBNL1 dose-dependent splicing response. A framework was developed to estimate MBNL concentration using splicing responses alone, validated in the cell-based model, and applied to myotonic dystrophy patient muscle. Using this framework, we evaluated the ability of individual and combinations of splicing events to predict functional MBNL concentration in human biopsies, as well as their performance as biomarkers to assay mild, moderate, and severe cases of DM.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution 4.0 International License
http://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/107820
DOI of Published Version
https://doi.org/10.1371/journal.pgen.1006316
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.